Interestingly, more differentiated tumors (low- and intermediate-risk) show higher expression of ELOVL4 when compared with those less differentiated tumors (high-risk), and high levels of ELOVL4 identify subsets of NB patients with a better prognosis. This evidence concerns the gene ELOVL4 and neuroblastoma.